Post by icemandios on Jun 18, 2019 13:30:29 GMT
A form 6-K (report by foreign issuer) filed today says:
The date is emphasized as it appears an ongoing trial has been modified to include the "auto-injector."
On June 14, 2019, the Company introduced its proprietary auto-injector in the Company’s enliGHten Trial. The enliGHten Trial is designed to provide long-term safety and efficacy data in approximately 300 patients. The safety database will support the potential future regulatory filings for TransCon hGH.
The enliGHten Trial began in 2017, presumably using the standard hypodermic needle. The anticipated end date is 12/2021, or at least it was. Not sure if the addition of a new device alters that expectation.
